

July 27, 2024

The Manager- Listing

**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra – Kurla Complex, Bandra (E),  
Mumbai – 400 051

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that on July 26, 2024, the Company has received a final assessment order passed by the assessment unit under section 143(3) read with section 144C(13) and section 144(B) of the Income Tax Act, 1961 (the Act), for assessment year 2020-21.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking You,

**For AstraZeneca Pharma India Limited**

Manasa. R  
Company Secretary

**Annexure – A**

Sl. No.	Particulars	Details
1.	Name of the opposing party	Assessment Unit, Income tax department
2.	Brief details of dispute/litigation	In the captioned order, adjustment on account of the legacy transfer pricing issues has been made under section 92CA(3) of the Act.
3.	Court/tribunal/agency where the litigation is filed	The matter will be challenged before the Income-tax Appellate Tribunal (ITAT) by filing an appeal.
4.	Expected financial implications, if any, due to compensation, penalty etc.	Matter will be suitably challenged in due course. The expected overall financial implication cannot be determined at this stage.
5.	Quantum of claims, if any	Rs. 9.33 crores (approx.) excluding interest and penalty.